Renal cell carcinoma (advanced) - axitinib [ID518]

Anticipated publication date:

Axitinib for the treatment of advanced renal cell carcinoma after failure of prior systemic treatment
 
Status
In development
Anticipated publication date
TBC
Process
STA
Referral date
February 2012
Topic area
  • Cancer
  • Urogenital
Notes

Scoped as part of Batch 21

Provisional Schedule

Closing date for invited submissions / evidence submission: (post-appeal) 8 November 2013
1st appraisal committee meeting: 13 November 2012
2nd appraisal committee meeting 13 February 2013
3rd appraisal committee meeting: 04 February 2014
4th appraisal committee meeting: 01 April 2014

Project Team

Executive Lead: TBC
Technical Lead: Nwamaka Umeweni
Communications manager: Alice Law
Project manager:

Nicole Fisher

Consultees

Manufacturers/sponsors
  • Pfizer (axitinib)
Patient/carer groups
  • James Whale Fund for Kidney Cancer
  • Kidney Cancer UK
  • Kidney Cancer Support Network
Professional groups
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians
Others
  • Department of Health
  • NHS Central Manchester CCG
  • NHS England
  • Welsh Government

Commentators

General
  • Department of Health,Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
Comparator manufacturers
  • Pfizer (sunitinib)
  • GSK (pazopanib)
Relevant research groups
  • MRC Clinical Trials Unit
Evidence Review Group
  • Kleijnen Systematic Reviews Lts
  • National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
  • National Collaborating Centre for Cancer
Associated public health groups
  • none

Timeline

Key events during the development of the guidance

Date
Update
20 June 2014
This appraisal is currently delayed in order to reconcile the axitinib marketing authorisation and English clinical practice for people who have received prior treatment before NICE finalise the recommendations resulting from Committee’s decision. This will extend the timelines for the appraisal.
4 October 2013
Following the appeal panel's decision on the appeal points heard at the appeal hearing on 10 June, this appraisal will go through the Single Technology Appraisal (STA) process again with an updated scope.The updated scope and matrix can be viewed under key documents titled post appeal.
Get involved